Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
None
Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the course of 50 weeks of treatment.

nt-probnp
hypertrophic obstructive cardiomyopathy
cardiopulmonary exercise testing
exercise test
cpet
  • 26 views
  • 28 Oct, 2021
  • 19 locations
None
Changes in NT-proBNP and Outcomes Safety and Tolerability in HFpEF Patients With Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization and Initiated In-hospital or Within 30 Days Post-discharge (PARAGLIDE-HF)

The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left

  • 38 views
  • 08 Dec, 2021
  • 94 locations
None
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides Angiotensin and Neprilysin

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

sacubitril/valsartan
chronic heart failure
ejection fraction
angiotensin
  • 5 views
  • 23 Jan, 2021
  • 1 location
None
Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor with the ability to reduce myocardial hypertrophy, cardiac remodeling and cardiorenal fibrosis. The compound is also believed

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation

The purpose of this study is to determine whether LCZ696 (valsartan/sacubitril) is safe and has beneficial effects on the heart and blood vessels in patients with high blood pressure and/or

valsartan
hypertension
heart failure
diabetes
natriuretic peptide
  • 0 views
  • 08 Nov, 2020
  • 1 location
None
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

The purpose of this study is to determine the effect of sacubitril/valsartan versus placebo on markers of cardiac injury, structure, and function among patients who recovered from acute COVID-19

  • 0 views
  • 23 Aug, 2021
  • 1 location
None
Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

The purpose of the study is to evaluate how well tolerated and effective an angiotensin receptor-neprilysin inhibitor (sacubitril-valsartan) is in patients with contemporary durable continuous

  • 2 views
  • 19 Jun, 2021
  • 1 location
None
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis

This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.

  • 0 views
  • 19 Jun, 2021
  • 38 locations
None
Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

This study is a randomized controlled multicenter clinical trial, in which about 340 patients with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group. All-cause death, cardiac death and …

angiotensin ii receptor antagonist
angiotensin
nt-probnp
ace inhibitor
enalapril
  • 0 views
  • 23 Jan, 2021
  • 1 location
None
Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine

By means of a personalized medicine strategy, investigators are going to evaluate if the treatment with an angiotensin II receptor antagonist (ARAII) in renal transplant patients with the presence of renal progenitor cells (PECs) in the urine is able to prevent the expected loss of glomerular filtration (GFR) observed in …

  • 0 views
  • 27 May, 2021
  • 1 location